Display options
Cite
Raymond W, Ostli-Eilertsen G, Griffiths S, et al. IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role. Eur J Rheumatol. 2017;4(1):29-35doi: 10.5152/eurjrheum.2017.16059.
Raymond, W., Ostli-Eilertsen, G., Griffiths, S., & Nossent, J. (2017). IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role. European journal of rheumatology, 4(1), 29-35. https://doi.org/10.5152/eurjrheum.2017.16059
Raymond, Warren, et al. "IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role." European journal of rheumatology vol. 4,1 (2017): 29-35. doi: https://doi.org/10.5152/eurjrheum.2017.16059
Raymond W, Ostli-Eilertsen G, Griffiths S, Nossent J. IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role. Eur J Rheumatol. 2017 Mar;4(1):29-35. doi: 10.5152/eurjrheum.2017.16059. Epub 2017 Mar 01. PMID: 28293450; PMCID: PMC5335884.
Copy Download .nbib Format: NLM
Share it on

Eur J Rheumatol. 2017 Mar;4(1):29-35. doi: 10.5152/eurjrheum.2017.16059. Epub 2017 Mar 01.

IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role.

European journal of rheumatology

Warren Raymond, Gro Ostli-Eilertsen, Sheynae Griffiths, Johannes Nossent

Affiliations

  1. Rheumatology Group, The University of Western Australia School of Medicine, Crawley, Western Australia.
  2. Department of Clinical Medicine, Bone & Joint Group, Arctic University, Tromsø, Norway.
  3. Rheumatology Group, The University of Western Australia School of Medicine, Crawley, Western Australia; Department of Clinical Medicine, Bone & Joint Group, Arctic University, Tromsø, Norway; Department of Rheumatology, Sir Charles Gairdner Hospital, Nedlands, Western Australia.

PMID: 28293450 PMCID: PMC5335884 DOI: 10.5152/eurjrheum.2017.16059

Abstract

OBJECTIVE: The interleukin 17 (IL-17) cytokine family is involved in a number of chronic inflammatory diseases. In spite of contradictory findings and a lack of causality in clinical studies, IL-17 inhibition for systemic lupus erythematosus (SLE) has regained attention as a potential therapeutic pathway, after demonstrating disease-modifying capabilities in ankylosing spondylitis. We investigated the clinical associations of interleukin 17 A (IL-17A) in patients with SLE.

MATERIAL AND METHODS: A cross-sectional study was performed involving SLE patients (n=102; age: 49 years; 86% female) recruited from a regional registry. IL-17A levels were determined by immunoassay, disease activity by Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K), and cumulative damage by Systemic Lupus International Collaborative Clinics Damage Index (SDI) scores. Non-parametric techniques were used to examine the association between IL-17A and disease activity and autoantibody profiles were compared with healthy controls (n=31): principal component analysis (PCA) was used to determine the interplay of immune cells across disease states and damage development in SLE patients.

RESULTS: SLE patients had higher IgG levels, lower T-cell and B-cell counts, but median IL-17A levels did not differ from the controls (28.4 vs. 28.4 pg/mL, p=0.9). In SLE patients, IL-17A did not correlate with SLEDAI-2K or SDI, but was inversely related with age (correlation coefficients, Rs.=-0.29, p<0.05), systolic blood pressure (Rs.=-0.31, p<0.05), years of smoking (Rs.=-0.43, p<0.05), cumulative heart (Rs.=-0.22, p<0.05), and malignancy damage (Rs.=-0.18, p<0.05). Serological correlations for IL-17A existed with immunoglobulin G (IgG) levels (Rs.=0.21, p<0.05), high sensitivity C-reactive protein (hs-CRP) levels (Rs.=0.28, p<0.05), proteinuria (Rs.=0.64, p<0.05), and pre-albumin (Rs.=-0.22, p<0.05). Longitudinal data showed only modest fluctuation in IL-17A levels, independent of SLEDAI-2K.

CONCLUSION: These results suggest that IL-17A, while participating in inflammation, may also serve a protective purpose in SLE patients.

Keywords: IL-17A; SLEDAI; Systemic Lupus Erythematosus; organ damage

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

References

  1. Arthritis Rheum. 2009 May;60(5):1472-83 - PubMed
  2. Rheumatology (Oxford). 2011 May;50(5):982-8 - PubMed
  3. J Biomed Biotechnol. 2011;2011:432595 - PubMed
  4. Nat Immunol. 2014 Sep;15(9):894 - PubMed
  5. Gut. 2012 Dec;61(12):1693-700 - PubMed
  6. Mol Biol Rep. 2010 Jan;37(1):81-5 - PubMed
  7. Eur Cytokine Netw. 2013 Mar;24(1):60-8 - PubMed
  8. J Leukoc Biol. 2007 Aug;82(2):354-60 - PubMed
  9. N Engl J Med. 2015 Oct;373(14):1329-39 - PubMed
  10. Blood. 2008 Nov 1;112(9):3696-703 - PubMed
  11. Clin Immunol. 2008 Jun;127(3):385-93 - PubMed
  12. Ann Rheum Dis. 2009 Apr;68(4):604-6 - PubMed
  13. J Clin Immunol. 2013 May;33(4):767-74 - PubMed
  14. BMC Immunol. 2015 Feb 12;16:7 - PubMed
  15. J Biomed Biotechnol. 2010;2010:null - PubMed
  16. J Immunol. 1995 Dec 15;155(12):5483-6 - PubMed
  17. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):258-64 - PubMed
  18. Clin Immunol. 2014 Sep;154(1):1-12 - PubMed
  19. J Biomed Biotechnol. 2012;2012:347141 - PubMed
  20. Cancer Res. 2008 May 15;68(10):3915-23 - PubMed
  21. Curr Opin Immunol. 2003 Apr;15(2):148-54 - PubMed
  22. Cytokine. 2013 Mar;61(3):785-91 - PubMed
  23. Clin Rheumatol. 2013 Jul;32(7):1045-52 - PubMed
  24. Clin Exp Immunol. 2013 Nov;174(2):292-301 - PubMed
  25. Arthritis Res Ther. 2013 Aug 23;15(4):R97 - PubMed
  26. Lancet. 2015 Sep 19;386(9999):1137-46 - PubMed
  27. Lupus. 2000;9(8):589-93 - PubMed
  28. J Biomed Biotechnol. 2010;2010:365083 - PubMed
  29. Ann Rheum Dis. 2011 Mar;70 Suppl 1:i37-43 - PubMed
  30. J Rheumatol. 2000 Feb;27(2):373-6 - PubMed
  31. Clin Exp Immunol. 2009 Aug;157(2):209-15 - PubMed
  32. Eur Heart J. 2013 Feb;34(8):570-7 - PubMed
  33. J Rheumatol. 2016 Feb;43(2):315-22 - PubMed
  34. Biomed Res Int. 2015;2015:314620 - PubMed
  35. J Gerontol A Biol Sci Med Sci. 2010 Apr;65(4):429-33 - PubMed
  36. J Immunol. 2009 Oct 1;183(7):4169-75 - PubMed
  37. Front Immunol. 2015 Oct 28;6:550 - PubMed
  38. Eur J Immunol. 2015 Sep;45(9):2683-93 - PubMed

Publication Types